JAK1 and rheumatoid arthritis: Upadacintinib (ABT-494) is a selective JAK1 inhibitor that was designed to address the hypothesis of whether greater JAK1 selectivity over other JAK family members would translate clinically to an improved benefit:risk profile compared to tofactinib, the first approved JAK inhibitor for the treatment of RA.